IBC patients were younger than non-IBC patients, and IBC samples showed more often than non-IBC samples poor-prognosis features (p < 0.01; Fisher's exact test): AJCC stage 3–4, ductal type, high grade, ER-negative, PR-negative and ERBB2-positive status, and aggressive molecular subtypes (basal, ERBB2-enriched). Here, ERBB2 is linked to inflammatory breast carcinoma.